Stockscreener 앱 받기
3.94
2.72%
-0.11
시간 외 거래:
3.86
-0.08
-2.03%
전일 마감가:
$4.05
열려 있는:
$4.05
하루 거래량:
244.70K
Relative Volume:
2.00
시가총액:
$33.93M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-17.91
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
-26.08%
1개월 성능:
-59.83%
6개월 성능:
-66.01%
1년 성능:
-65.83%
1일 변동 폭
$3.76
$4.15
1주일 범위
$3.76
$5.54
52주 변동 폭
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
3.94 | 34.88M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PR Newswire
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Market Outlook: Is Atossa Therapeutics Inc part of any ETFWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Mammoth Energy sets March 6 call to review full-year 2025 results - Stock Titan
Atossa Therapeutics Maintains Strong Market Position for (Z)-End - GuruFocus
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - Sahm
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Genetics (NASDAQ:ATOS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Asianet Newsable
Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year LowWhat's Next? - MarketBeat
Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens - TechStock²
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January - MarketBeat
Aug PreEarnings: How volatile is SKYQ stockWeekly Market Summary & Weekly Market Pulse Updates - baoquankhu1.vn
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd - MarketBeat
Can Atossa Therapeutics Inc. lead its sector in growthGap Up & Verified Swing Trading Watchlist - mfd.ru
Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook - simplywall.st
Risk Hedge: Can Adagene Inc. Depositary Receipt stock outperform in a bear market2025 Sector Review & Long-Term Safe Investment Plans - baoquankhu1.vn
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - PR Newswire
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (2026-01-21) - Seeking Alpha
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Big Picture: Is Atossa Therapeutics Inc part of any ETF2025 Fundamental Recap & Reliable Price Breakout Signals - baoquankhu1.vn
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z) - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program - The Globe and Mail
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving AverageHere's Why - MarketBeat
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - Улправда
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atossa Therapeutics Inc 주식 (ATOS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
1.24%
0.19%
자본화:
|
볼륨(24시간):